Structure rises after obesity pill shows up to 16.3% weight loss in study

Structure Therapeutics

16/03/2026 14:56

Updates

** Shares of drug developer Structure Therapeutics GPCR.O rise 3.9% to $55.84
** Co says its oral obesity drug aleniglipron delivered up to 16.3% weight loss, when compared with a placebo after 44 weeks of treatment in a mid‑stage study

** Drug developers are racing to enter the highly competitive weight-loss drug market which is currently dominated by injectable drugs like Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound

** Analysts have previously estimated that weight loss of up to 16% would make Structure's aleniglipron competitive with other pills

** RBC Capital Markets says the data adds to growing interest in the oral obesity-drug space, but does not show a meaningfully differentiated profile versus Lilly's orforglipron

** "The initial reaction from the 240mg and 180mg doses looking similar, coupled with discontinuations, could weigh on shares" - BMO Capital Markets

** At 36 weeks, aleniglipron had shown weight loss of up to 15.3% at 240 mg dose - GPCR
** GPCR expects to begin late-stage study in H2

** Including session moves, GPCR down 21.3% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))